Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $4.00 Consensus Price Target from Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has earned an average recommendation of “Hold” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $4.00.

Several research firms have weighed in on HOWL. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL opened at $0.98 on Friday. Werewolf Therapeutics has a one year low of $0.27 and a one year high of $2.38. The company has a market cap of $47.72 million, a P/E ratio of -1.29 and a beta of 0.51. The firm’s fifty day moving average price is $0.57 and its two-hundred day moving average price is $0.61.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The company had revenue of $21.00 million for the quarter, compared to analyst estimates of $21.00 million. As a group, equities research analysts expect that Werewolf Therapeutics will post -0.89 earnings per share for the current year.

Insider Activity at Werewolf Therapeutics

In related news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the sale, the insider directly owned 303,719 shares in the company, valued at $106,301.65. The trade was a 57.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Luke Evnin sold 107,429 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total value of $33,302.99. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 838,505 shares of company stock valued at $296,250. 23.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HOWL. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Bank of America Corp DE bought a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $112,000. Renaissance Technologies LLC grew its position in Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after buying an additional 221,766 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Werewolf Therapeutics during the third quarter worth approximately $304,000. Finally, Vanguard Group Inc. increased its stake in Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the period. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.